Led by sales of its narcolepsy drug, total revenues for the quarter ended June 30, 2011 were $64.6 million for Jazz Pharmaceuticals, compared to $40.5 million for the second quarter of 2010.
Net sales of Xyrem (sodium oxybate) oral solution increased 67% to $56.2 million for the second quarter of 2011, compared to net sales of $33.7 million for the second quarter of 2010.
“Our strong quarterly performance demonstrates our ongoing commitment to growing Xyrem as the core of our company’s strategy,” said Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals.
